Regencell Bioscience Holdings Limited
NASDAQ:RGC
4.77 (USD) • At close December 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 | 2007 | 2006 | 2005 | 2004 | 2002 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 3,163 | 3,197.1 | 3,127.3 | 2,990.1 | 3,038.1 | 2,824.2 | 2,807.9 | 2,893.9 | 2,771 | 2,661 | 2,598 | 2,468 | 2,489 | 2,140 |
Cost of Revenue
| 0.746 | 0.77 | 0.604 | 0.026 | 0.01 | 0 | 123 | 1,226.8 | 1,207.5 | 111 | 111 | 101 | 101 | 1,157.1 | 106 | 103 | 104 | 94 | 92 | 84 |
Gross Profit
| -0.746 | -0.77 | -0.604 | -0.026 | -0.01 | 0 | 3,040 | 1,970.3 | 1,919.8 | 2,879.1 | 2,927.1 | 2,723.2 | 2,706.9 | 1,736.8 | 2,665 | 2,558 | 2,494 | 2,374 | 2,397 | 2,056 |
Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.961 | 0.616 | 0.614 | 0.963 | 0.963 | 0.964 | 0.964 | 0.6 | 0.962 | 0.961 | 0.96 | 0.962 | 0.963 | 0.961 |
Reseach & Development Expenses
| 1.066 | 1.582 | 2.512 | 0.438 | 0.386 | 0.228 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 0 | 4.429 | 5.08 | 0.941 | 0.312 | 0.159 | 86.6 | 512.2 | 500.3 | 74.4 | 73.7 | 68.8 | 66.7 | 443 | 62 | 63 | 65 | 63 | 62 | 65 |
Selling & Marketing Expenses
| 0 | 0.263 | 0.025 | 0.002 | 0.114 | 0.004 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 2.925 | 4.692 | 5.106 | 0.943 | 0.426 | 0.163 | 86.6 | 512.2 | 500.3 | 74.4 | 73.7 | 68.8 | 66.7 | 443 | 62 | 63 | 65 | 63 | 62 | 65 |
Other Expenses
| 0 | 0.211 | 0.023 | 0.035 | 0 | 0 | 1,223.5 | 1,113.9 | 1,080.5 | 1,119.5 | 1,085.1 | 985.3 | 1,166.3 | 980.4 | 2,425 | 2,276 | 2,224 | 2,083 | 2,048 | 1,791 |
Operating Expenses
| 3.991 | 6.274 | 7.618 | 1.381 | 0.812 | 0.391 | 1,310.1 | 1,626.1 | 1,580.8 | 1,193.9 | 1,158.8 | 1,054.1 | 1,233 | 1,423.4 | 2,487 | 2,339 | 2,289 | 2,146 | 2,110 | 1,856 |
Operating Income
| -4.737 | -6.274 | -7.618 | -1.381 | -0.812 | -0.391 | 271.7 | 344.2 | 339 | 306.4 | 339.8 | 334.2 | 215.8 | 313.4 | 284 | 322 | 308 | 321 | 379 | 283 |
Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.086 | 0.108 | 0.108 | 0.102 | 0.112 | 0.118 | 0.077 | 0.108 | 0.102 | 0.121 | 0.119 | 0.13 | 0.152 | 0.132 |
Total Other Income Expenses Net
| 0.374 | 0.211 | 0.023 | 0.035 | 0 | 0 | -57.8 | -62.5 | -85.7 | -127.8 | -75.2 | -98.3 | -140.1 | -156.2 | -161 | 283 | -164 | -179 | -73 | -75 |
Income Before Tax
| -4.363 | -6.062 | -7.595 | -1.347 | -0.812 | -0.391 | 213.9 | 281.7 | 253.3 | 178.6 | 264.6 | 235.9 | 75.7 | 157.2 | 123 | 605 | 144 | 142 | 306 | 208 |
Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.068 | 0.088 | 0.081 | 0.06 | 0.087 | 0.084 | 0.027 | 0.054 | 0.044 | 0.227 | 0.055 | 0.058 | 0.123 | 0.097 |
Income Tax Expense
| 0.312 | -0.191 | -0.172 | -0.21 | -0 | -0 | 101.6 | 111.2 | 100.1 | 73.4 | 107 | 91.2 | 48.7 | 61.9 | 50 | 242 | 57 | 59 | 121 | 89 |
Net Income
| -4.302 | -5.871 | -7.423 | -1.347 | -0.812 | -0.391 | 112.3 | 170.4 | 153.4 | 105.6 | 157.7 | 144.8 | 77.6 | 95.5 | 72 | 363 | 86 | 82 | 185 | 117 |
Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.036 | 0.053 | 0.049 | 0.035 | 0.052 | 0.051 | 0.028 | 0.033 | 0.026 | 0.136 | 0.033 | 0.033 | 0.074 | 0.055 |
EPS
| -0.33 | -0.45 | -0.57 | -0.11 | -0.064 | -0.031 | 0.72 | 1.09 | 0.98 | 0.68 | 1.02 | 0.94 | 0.51 | 0.62 | 62.1 | 63.1 | 65.9 | 0.57 | 1.34 | 0.83 |
EPS Diluted
| -0.33 | -0.45 | -0.57 | -0.11 | -0.064 | -0.031 | 0.72 | 1.09 | 0.98 | 0.68 | 1.01 | 0.93 | 0.5 | 0.62 | 62.1 | 63.1 | 65.9 | 0.55 | 1.3 | 0.79 |
EBITDA
| -3.618 | -5.293 | -6.99 | -1.355 | -0.803 | -0.391 | 468.7 | 512.3 | 470.3 | 391 | 469.2 | 422.2 | 352.5 | 512.1 | 200 | 676 | 215 | 220 | 392 | 401 |
EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.148 | 0.16 | 0.15 | 0.131 | 0.154 | 0.149 | 0.126 | 0.177 | 0.072 | 0.254 | 0.083 | 0.089 | 0.157 | 0.187 |